R L Cazzato1, F Bonichon2, X Buy3, Y Godbert4, B H de Figuereido5, V Pointillart6, J Palussière7. 1. Department of "Diagnostica per Immagini e Radiologia Interventistica", Università "Campus Bio-Medico di Roma", Via Alvaro del Portillo, 200, 00128 Rome, Italy; Department of Radiology, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: r.cazzato@unicampus.it. 2. Department of Nuclear Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: f.bonichon@bordeaux.unicancer.fr. 3. Department of Radiology, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: x.buy@bordeaux.unicancer.fr. 4. Department of Nuclear Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: y.godbert@bordeaux.unicancer.fr. 5. Department of Radiotherapy, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: b.henriques@bordeaux.unicancer.fr. 6. Department of Neurosurgery, University Hospital of Bordeaux, Place Amélie-Raba-Léon, 33000 Bordeaux, France. Electronic address: vincent.pointillart@chu-bordeaux.fr. 7. Department of Radiology, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France. Electronic address: j.palussiere@bordeaux.unicancer.fr.
Abstract
OBJECTIVE: Percutaneous image-guided treatments (PIGT) are performed by interventional radiologists with a minimally invasive approach. Currently, very little published data on their outcomes are available and conclusions regarding their application are cautious. The aim of the present study was to review our experience in PIGT of bone metastases from thyroid cancer. MATERIALS AND METHODS: Institutional databases were reviewed to identify patients with differentiated thyroid cancer and bone metastases who received PIGT between October 2001 and April 2014. Complications, local evolution of the treated lesions, and overall survival (OS) were investigated. RESULTS: Twenty-five patients (12 male, 13 female) underwent 49 PIGT sessions consisting of cementoplasty (77.5%), cryoablation (14.3%) or radiofrequency ablation (8.2%). Most of the treated lesions (50/54, 92.6%) were symptomatic at the time of PIGT. Median follow-up after PIGT was 4.6 years. Local complete remission rate was 55.6%. Two complications (one major and one minor) were noted, but none of these were consistent with fractures or nervous system injuries. OS after PIGT was 71.6%, 66.8% and 60.1% at 1, 2 and 3 years, respectively. A difference in survival was observed between patients with metastatic bone involvement only at the time of first PIGT compared to those with multi-organ involvement (P = 0.03). CONCLUSIONS: Patients with bone metastases from differentiated thyroid cancer may benefit from PIGT. Although patients are usually referred for PIGT due to their symptomatic status, a more relevant "curative" role may exist for PIGT. Further prospective studies are needed to confirm this perception.
OBJECTIVE: Percutaneous image-guided treatments (PIGT) are performed by interventional radiologists with a minimally invasive approach. Currently, very little published data on their outcomes are available and conclusions regarding their application are cautious. The aim of the present study was to review our experience in PIGT of bone metastases from thyroid cancer. MATERIALS AND METHODS: Institutional databases were reviewed to identify patients with differentiated thyroid cancer and bone metastases who received PIGT between October 2001 and April 2014. Complications, local evolution of the treated lesions, and overall survival (OS) were investigated. RESULTS: Twenty-five patients (12 male, 13 female) underwent 49 PIGT sessions consisting of cementoplasty (77.5%), cryoablation (14.3%) or radiofrequency ablation (8.2%). Most of the treated lesions (50/54, 92.6%) were symptomatic at the time of PIGT. Median follow-up after PIGT was 4.6 years. Local complete remission rate was 55.6%. Two complications (one major and one minor) were noted, but none of these were consistent with fractures or nervous system injuries. OS after PIGT was 71.6%, 66.8% and 60.1% at 1, 2 and 3 years, respectively. A difference in survival was observed between patients with metastatic bone involvement only at the time of first PIGT compared to those with multi-organ involvement (P = 0.03). CONCLUSIONS:Patients with bone metastases from differentiated thyroid cancer may benefit from PIGT. Although patients are usually referred for PIGT due to their symptomatic status, a more relevant "curative" role may exist for PIGT. Further prospective studies are needed to confirm this perception.
Authors: Roberto Luigi Cazzato; Julien Garnon; Nitin Ramamurthy; Guillaume Koch; Georgia Tsoumakidou; Jean Caudrelier; Francesco Arrigoni; Luigi Zugaro; Antonio Barile; Carlo Masciocchi; Afshin Gangi Journal: Med Oncol Date: 2016-11-11 Impact factor: 3.064
Authors: Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini Journal: Eur Thyroid J Date: 2021-05-25
Authors: Caroline A Burgard; Julien Dinkel; Frederik Strobl; Philipp M Paprottka; Nicolai Schramm; Maximilian Reiser; Christoph G Trumm Journal: Diagn Interv Radiol Date: 2018 May-Jun Impact factor: 2.630
Authors: Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark Journal: Thyroid Date: 2021-03 Impact factor: 6.568